Last reviewed · How we verify
Prevention of Kidney Transplant Rejection
Approved treatments
- Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Imuran · Legacy Pharma
- Sandimmune · Novartis
- Prograf · Astellas Pharma
Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell. - Afinitor · Novartis
Afinitor works by blocking the mTOR protein, which is involved in cell growth and division. - Mycophenolate · Sanofi
- Sandimmune · Novartis AG (originally Sandoz)
Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection. - Afinitor · Central European Society for Anticancer Drug Research
- ciclosporine · Hospices Civils de Lyon
- Cellcept · Roche Palo
Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides. - Mycophenolate · Novartis
- Rapamune · Pfizer
Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells. - Neoral · Novartis Pharmaceuticals
- Cyclosporin · Karolinska University Hospital
- Rapamycin · Institut National de la Santé Et de la Recherche Médicale, France
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of Kidney Transplant Rejection patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of Kidney Transplant Rejection treatment landscape brief
- Prevention of Kidney Transplant Rejection treatment updates RSS
Frequently asked questions about Prevention of Kidney Transplant Rejection
What drugs treat Prevention of Kidney Transplant Rejection?
Tracked treatments include Rapamune, Imuran, Sandimmune, Prograf, Afinitor, Mycophenolate, ciclosporine, Cellcept.
What is the treatment for Prevention of Kidney Transplant Rejection?
Standard treatment for Prevention of Kidney Transplant Rejection includes Rapamune, Imuran, Sandimmune, Prograf, Afinitor. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of Kidney Transplant Rejection patent cliff · Prevention of Kidney Transplant Rejection CI report
- Treatment: Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Treatment: Imuran · Legacy Pharma
- Treatment: Sandimmune · Novartis
- Treatment: Prograf · Astellas Pharma
- Treatment: Afinitor · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing